Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

482 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The value of induction chemotherapy for survival in patients with non-small cell lung cancer treated with radiotherapy.
Holgersson G, Sandelin M, Hoye E, Bergström S, Henriksson R, Ekman S, Nyman J, Helsing M, Friesland S, Brodin O, Holgersson M, Lundström KL, Janson C, Ekberg L, Mörth C, Blystad T, Ewers SB, Löden B, Bergqvist M. Holgersson G, et al. Among authors: nyman j. Anticancer Res. 2012 Apr;32(4):1339-46. Anticancer Res. 2012. PMID: 22493368
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team. Butts C, et al. Among authors: nyman j. Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9. Lancet Oncol. 2014. PMID: 24331154 Free article. Clinical Trial.
Analysis of early respiratory-related mortality after radiation therapy of non-small-cell lung cancer: feasibility of automatic data extraction for dose-response studies.
Stervik L, Pettersson N, Scherman J, Behrens CF, Ceberg C, Engelholm S, Gunnarsson K, Hallqvist A, Nyman J, Persson GF, Pøhl M, Wahlstedt I, Vogelius IR, Bäck A. Stervik L, et al. Among authors: nyman j. Acta Oncol. 2020 Jun;59(6):628-635. doi: 10.1080/0284186X.2020.1739331. Epub 2020 Mar 23. Acta Oncol. 2020. PMID: 32202189
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial.
Grønberg BH, Killingberg KT, Fløtten Ø, Brustugun OT, Hornslien K, Madebo T, Langer SW, Schytte T, Nyman J, Risum S, Tsakonas G, Engleson J, Halvorsen TO. Grønberg BH, et al. Among authors: nyman j. Lancet Oncol. 2021 Mar;22(3):321-331. doi: 10.1016/S1470-2045(20)30742-7. Lancet Oncol. 2021. PMID: 33662285 Clinical Trial.
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer.
Killingberg KT, Halvorsen TO, Fløtten Ø, Brustugun OT, Langer SW, Nyman J, Hornslien K, Madebo T, Schytte T, Risum S, Tsakonas G, Engleson J, Grønberg BH. Killingberg KT, et al. Among authors: nyman j. Lung Cancer. 2022 Apr;166:49-57. doi: 10.1016/j.lungcan.2022.02.002. Epub 2022 Feb 8. Lung Cancer. 2022. PMID: 35183991 Free article. Clinical Trial.
482 results